In exploratory analysis, although not significant, breast cancer with ER and/or PR positivity, T-DM1 administered as third- or later-line therapy, and HER2 gene amplification negativity verified by ctDNA analysis tended to exhibit primary resistance to T-DM1. Here, PGR is linked to breast cancer.